Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
Active Specific Immunotherapy for Follicular Lymphomas With Liposomes Containing Tumor-Derived Antigen and IL-2
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for follicular lymphoma .
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have stage III, stage IV, or recurrent follicular lymphoma.
調査の概要
詳細な説明
OBJECTIVES:
- Assess the safety of immunotherapy with autologous tumor cell vaccine and interleukin-2 in patients with stage III, IV, or recurrent follicular lymphoma.
- Determine the clinical response of patients treated with this regimen.
- Assess the immune response of patients treated with this vaccine.
OUTLINE: This is a multicenter study. Patients are stratified according to prior therapy (no prior biologic therapy or chemotherapy for lymphoma vs prior prednisone, doxorubicin, cyclophosphamide, and etoposide (PACE) chemotherapy). Patients without prior therapy are further stratified according to accessibility of lymph nodes (easily accessible (stratum Ia) vs not easily accessible (stratum Ib)).
All patients undergo lymph node biopsy to obtain tissue for vaccine manufacture. Treatment begins approximately 1 month after biopsy.
- Stratum Ia: Patients receive autologous tumor cell vaccine and interleukin-2 (IL-2) intranodally and subcutaneously (SC) on day 1.
- Stratum Ib and stratum II: Patients receive autologous tumor cell vaccine and IL-2 SC on day 1.
Treatment in each stratum continues every 4 weeks for a maximum of 5 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 and 4 months, every 3 months for 1 year, and every 6 months thereafter until relapse or progression of disease.
PROJECTED ACCRUAL: A total of 20 patients (10 per stratum) will be accrued for this study within 1.5-2 years.
研究の種類
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- Medicine Branch
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Histologically proven follicular center cell lymphoma with surface immunoglobulin (Ig) M, G, or A phenotype
- Grade I (follicular small cleaved cell)
- Grade II (follicular mixed small and large cell)
- Grade III (follicular large cell)
- Stage III, IV, or recurrent disease
- Previously untreated with chemotherapy or monoclonal antibody therapy OR
- Recurrent, residual disease or progressive disease after prior prednisone, doxorubicin, cyclophosphamide, and etoposide (PACE) chemotherapy
- Peripheral lymph node of at least 2 cm and accessible for biopsy/harvest
- No primary or secondary CNS lymphoma
Must not have any of the following:
- Rapidly progressing lymphadenopathy
- Bone marrow failure secondary to lymphoma
- B symptoms
- Neurovascular or organ compromise secondary to lymphoma
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 70-100%
Life expectancy:
- More than 1 year
Hematopoietic:
- Not specified
Hepatic:
- ALT/AST no greater than 3.5 times upper limit of normal
- Bilirubin no greater than 1.5 mg/dL unless secondary to Gilbert's disease
- Hepatitis B surface antigen negative
- Hepatitis C antibody negative
Renal:
- Creatinine no greater than 1.5 mg/dL
Other:
- HIV negative
- No active infection
- No other prior or concurrent malignancy except curatively treated squamous cell or basal cell skin cancer or effectively treated carcinoma in situ of the cervix
- No medical or psychiatric condition that would preclude study
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
- No other concurrent biologic therapy for lymphoma
Chemotherapy:
- See Disease Characteristics
- At least 3 months since prior PACE chemotherapy
- No concurrent chemotherapy
Endocrine therapy:
- At least 2 weeks since prior steroid treatment
- Less than 2 months of prior prednisone
- No concurrent endocrine therapy for lymphoma
Radiotherapy:
- Prior radiotherapy to no more than 1 site allowed
- At least 2 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Lymph node biopsy performed within past month
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
協力者と研究者
捜査官
- スタディチェア:Sattva S. Neelapu, MD、National Cancer Institute (NCI)
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CDR0000068505
- NCI-01-C-0069
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
アルデスロイキンの臨床試験
-
Carman GiacomantonioNova Scotia Health Authority引きこもった
-
Groupe Francophone des MyelodysplasiesEpiCept Corporation引きこもった